PDSB - PDS Biotech announces preliminary efficacy readout from phase 2 combo trial of PDS0101

PDS Biotechnology ([[PDSB]] -10.8%) announced that the National Cancer Institute’s ((NCI)) Phase 2 clinical study of PDS0101, for the treatment of advanced human papillomavirus ((HPV))-associated cancers that have progressed or returned after treatment, achieved its preliminary objective response.The trial, which studies PDS0101 in combination with two investigational immune-modulating agents, will now progress to full enrollment of about 20 patients.According to the clinical trial design, the achievement of an objective response as measured by radiographic tumor responses according to RECIST 1.1 or iRECIST among at least three of the first eight patients allows the trial to progress to full enrollment.In preclinical studies performed at the NCI comparing each drug alone versus all three agents used in combination, the triple combination achieved the highest induction of tumor-specific CD8+ killer T-cells and superior antitumor effect, the company said.

For further details see:

PDS Biotech announces preliminary efficacy readout from phase 2 combo trial of PDS0101